Skip to content

Research

Links and information to research in paediatric and adolescent dermatology.

Research we have funded

UK-DCTN BSPAD  Paediatric Dermatology Research Awards 2021

  • Acceptability of teleconsultations for follow-up of paediatric eczema, compared to face-to-face consultation (Natalie King-Stokes).
  • Identifying patient-reported screening & assessment instruments for mental health in children/young people with acne (Damian Wood and Jane Ravenscroft, Nottingham).

BSF-BSPAD Small Grant 2022

A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.

PI:  Dr Tess McPherson . Co-applicants: Dr Chris Phillips, Dr Mina Fazel

Oxford University Hospitals NHS Foundation Trust.

 

BSF-BSPAD Small Grant 2023

A qualitative study to evaluate the content validity of the Psoriasis Area Severity Index (PASI), as a measure of disease severity in children and young people with psoriasis.

PI: Dr. Carsten Flohr, Ph.D.

St John’s. Institute of Dermatology

Funding opportunities

Upcoming grants, prizes, fellowships

NIHR GOSH BRC) Clinical Training PhD Fellowship Programme – Deadline 9th January

The NIHR Great Ormond Street Hospital Biomedical Research Centre (NIHR GOSH BRC) Clinical Training PhD Fellowship Programme aims to support training and development of the next generation of paediatric translational researchers. The Programme will fund up to four clinicians and wider health care professionals to undertake a three-year PhD at the UCL Great Ormond Street Institute of Child Health (UCL GOS ICH), with applicants expected to develop a project proposal as part of their application. Projects may also be collaborative and involve a supervisor and research time at our partner sites within the BRC Paediatric Excellence Initiative (Birmingham, Sheffield and Alder Hey Children’s Hospitals).

If interested and wish to discuss possible paediatric dermatology applications, cross-centre applications within the BRC Paediatric Excellence Initiative very desirable, please contact Maanasa Polubothu s.polubothu@ucl.ac.uk

Rosetrees Project Grant – Deadline 31st January 2024

Rosetrees is a UK charity supporting cutting edge medical research for more than 30 years. Project grants support innovative and established research projects with an established proof-of-concept. It is expected that our funding will enable projects to develop further towards clinical translation. This will be the only project grant round this year.

This year they are particularly interested in projects in eczema.

 

Research News

Awards, Important Studies, Clinical trials, Conferences

BADBIR study

Did you know that children with psoriasis may be eligible for the BADBIR study?

Since October 2015, BADBIR has been accepting enrolment of pediatric patients with psoriasis.

As these patients are being exposed to immunosuppressive therapy on a comparatively immature immune system, it is important that the long-term safety is evaluated. In addition, there is potentially a high lifetime exposure to these therapies which may place them at a higher risk than adults.

Currently, BADBIR’s recruitment total for participants is only around 30 registrations across the whole of the U.K. and Ireland with just 16 centers contributing. We understand that it is possible that you are not necessarily managing these patients in your clinics but please could you liaise with colleagues to explore the feasibility of registering these eligible patients.

Full details of the eligibility criteria for pediatric patients on BADBIR can be found at http://www.badbir.org/

If you require any assistance or advice please contact the BADBIR study team at badbir@manchester.ac.uk or on 0161 306 1896.

A-STAR

A-STAR stands for The UK-Irish Atopic Eczema Systemic Therapy Register. We are an observational study running in the UK and Ireland, seeking to assess the short and long-term safety and efficacy of systemic immuno-modulators for people of all ages with atopic eczema.

We will also look at the ‘real life’ cost of treating eczema, examining how much these therapies cost, compared to how well they work. Once patients sign up to participate in A-STAR, we will follow their medical care via their local dermatologists.

The overall aim is to help clinicians in their treatment decisions of patients with atopic eczema and through this to improve patient care.

Acne-ID

An acne trial recruiting adolescents and young people. Aiming to start recruitment in July 2024.

This recently HTA funded study looking at the benefits and harms of low-dose isotretinoin for acne is now in the set-up phase. It is a non-inferiority trial and will compare two different dosing strategies (low-dose vs standard-dose). It will report on the effectiveness, side effects experienced, mood changes, impact on quality of life, treatment satisfaction, risk of recurrence and cost implications of the two dosing strategies. It will incorporate the new MHRA recommendations for isotretinoin prescribing. Acne-ID aims to recruit 800 patients from 20 sites across the UK. This ambitious study will start recruiting in July 2024 and is led by Esther Burden-Teh and Kim Thomas, University of Nottingham.

For more information email: acne-id@nottingham.ac.uk

Here are two ways the trial team would like help from BSPAD members. We have also shared these surveys through the UK DCTN, and please only complete them once. 

A 5 minute survey on acne severity which will inform a training package for the chosen primary outcome. The survey will close on Monday 20th November.

https://forms.office.com/e/yWzuypnQiW

For members interested in becoming a recruiting site, here is a link to the site selection questionnaire. The survey will close on Friday 1st December. Attached to this email is more information about the trial (synopsis and flow diagram).

https://app.onlinesurveys.jisc.ac.uk/s/nottingham/acne-id-site-selection-questionnaire

    We process personal data in order to respond to your enquiry. Take a look at our privacy page for more details. We regret that as explained in our disclaimer, we can't respond to individual patient enquiries or provide clinical advice.

    Icon of people talking